G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout ...

Earlier this month, Genentech offered countless academics and other researchers up to $125,000 in grants to generate papers ...

Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8 billion valuation, ...

My patients are replacing olive oil with beef tallow, even if they don't tell me during cardiac rehab,” writes a clinical ...

Biogen and Denali Therapeutics said a closely watched experimental therapy for Parkinson’s disease failed to slow the ...

The company behind the analytics, Vizient, touts MGH's increasing hospice enrollment to improved mortality performance.

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from ...

Jeffery Taubenberger, the acting head of the NIAID, the NIH’s infectious disease institute, is reported to have stepped down.

Besides showing skepticism on the budget, senators grilled the NIH director about a leadership vacuum, two viral outbreaks, and the pace of funding.

This story was reported by Lizzy Lawrence, Matthew Herper, Isabella Cueto, Elizabeth Cooney, Andrew Joseph, Daniel Payne, and Helen Branswell. For more than a half-century, the Centers for Disease ...

President Trump's cuts to foreign aid probably hampered the detection of the Ebola outbreak and the response to it.